Implementing a personalized medicine program in a community health system.

Area of Science:

• Pharmacogenomics
• Rural Health
• Personalized Medicine

Background:

• Implementing personalized medicine in rural, underserved areas presents unique challenges.
• The US FDA has identified specific drug-gene pairs with significant safety implications, particularly in non-oncology settings.

Purpose of the Study:

• To describe the development and implementation of a de novo personalized medicine program.
• To focus on the safe use of medications affected by genetic variations.
• To address FDA-designated drug-gene pairs with black-box warnings.

Main Methods:

• Focused on drug-gene pairs with FDA black-box warnings (codeine, clopidogrel, abacavir, carbamazepine).
• Initiated policy change to remove codeine from pediatric formulary.
• Conducted pilot studies for primary care provider education on pharmacogenetic testing.
• Established a consultative outpatient clinic for patient pharmacogenetic services.

Main Results:

• Successful policy change regarding codeine use in pediatrics.
• Increased familiarity of primary care providers with pharmacogenetic testing.
• Development of a patient-facing consultative clinic.

Conclusions:

• Personalized medicine programs can be successfully implemented in rural health systems.
• Policy changes, alongside education and clinical services, are crucial for safe pharmacogenetic integration.
• Addressing FDA-warned drug-gene pairs is a vital first step for non-oncology pharmacogenomics.